INNT
TOTAL INVALIDATION PROCESSED BY THE IB
09/05/2025
Back to search
Official data from USPTO
VECTURA V
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
32
Latest update
09/10/2025
Trademark type
Combined
Nice classes
5, 10, 42
Filing date
11/03/2016
Registration date
02/13/2018
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/30/2024
Last transaction
09/10/2025
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
GB
Examiner
MARTIN, CHRISTINE
Law office
L40
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the letter "V" made up of 6 oblique lines and a small triangle appearing next to the stylized word "VECTURA".
Holders and representatives
Holders
Vectura Limited
Representatives
Molly B. Markley Young Basile Hanlon & MacFarlane P.C.
Technical classification
Nice Classes
Class 5Class 10Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical and biological preparations for medical purposesnamely for the treatment of diseases or conditions of the respiratory system; pharmaceutical and biological preparations for medical purposesnamely the treatment of diseases or conditions of the respiratory systemdiseases or conditions of the cardiovascular systemdiabetescancerarthritisdiseases or conditions of the gastro-intestinal systemdiseases or conditions of the central nervous systemdiseases or conditions of the endocrine systemdiseases or conditions of the genito-urinary systeminfectionsskin disorders and gynaecological conditions; pharmaceutical and biological preparations for medical purposesnamely for the alleviation or prevention of pain or inflammation; pharmaceutical and biological preparations for medical purposespowders for asthma inhalers; pharmaceutical and biological preparations for medical purposespowders for transdermal injection for the alleviation or prevention of painfor the treatment of diseases or conditions of the respiratory systemdiseases or conditions of the cardiovascular systemdiabetescancerarthritisdiseases or conditions of the gastro-intestinal systemdiseases or conditions of the central nervous systemdiseases or conditions of the endocrine systemdiseases or conditions of the genito-urinary systeminfectionsskin disorders and gynecological conditions; pharmaceutical and biological preparations for medical purposesnamely for oral ingestion for the treatment of diseases or conditions of the respiratory systemdiseases or conditions of the cardiovascular systemdiabetescancerarthritisdiseases or conditions of the gastro-intestinal systemdiseases or conditions of the central nervous systemdiseases or conditions of the endocrine systemdiseases or conditions of the genitourinary systeminfectionsskin disorders and gynecological conditions; pharmaceutical and biological preparations for medical purposesnamely for topical administration for the treatment of diseases or conditions of the respiratory systemdiseases or conditions of the cardiovascular systemdiabetescancerarthritisdiseases or conditions of the gastro-intestinal systemdiseases or conditions of the central nervous systemdiseases or conditions of the endocrine systemdiseases or conditions of the genito-urinary systeminfectionsskin disorders and gynecological conditions; pharmaceutical and biological preparations for medical purposemedicaments for inhalation therapy; pharmaceutical and biological preparations for medical purposespulmonary delivery compositions for use in facilitating the inhalation of pharmaceuticalsdrug delivery agents consisting of compounds that facilitate delivery by inhalation of a wide range of pharmaceuticals; pharmaceutical and biological preparations for medical purposenamely medicaments for the treatment of erectile dysfunctionmedicaments for the treatment of chronic obstructive pulmonary diseasemedicaments for the treatment of premature ejaculationmedicaments for the treatment of cystic fibrosismedicaments for the treatment of female sexual dysfunctionmedicaments for the treatment of migrainesmedicaments for the treatment of asthma
Class 10
Medical apparatus and instrumentsnamely drug delivery devicesnamely drug delivery systems; inhalers for medical use; metered dose inhalers for medical use; active dry powder inhalers for medical use; passive dry powder inhalers for medical use; nebulisers for respiration therapy; respirators for artificial respiration; parts and fittings for all the aforesaid goods
Class 42
Scientific researchdevelopmentdesignanalysistesting and investigation relating to medical preparations and drug delivery devices; medical research; research relating to drug delivery devices; research relating to drug formulation; pharmaceutical development; preparation and formulation of pharmaceuticals; device and product testing
Publications
History of USPTO decisions and trademark events.
32 publications found
INTS
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
08/16/2025
INPC
INVALIDATION PROCESSED
08/16/2025
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
04/30/2025
C71T
CANCELLED SECTION 71
08/30/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
12/22/2023
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
02/13/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
10/08/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
07/13/2018
FICS
FINAL DISPOSITION NOTICE SENT TO IB
05/23/2018
FIMP
FINAL DISPOSITION PROCESSED
05/23/2018
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
05/13/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
02/13/2018
GPNX
NOTIFICATION PROCESSED BY IB
12/08/2017
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/28/2017
PUBO
PUBLISHED FOR OPPOSITION
11/28/2017
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
11/22/2017
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
11/22/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/08/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/20/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/11/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/11/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/11/2017
RFNT
REFUSAL PROCESSED BY IB
05/13/2017
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
04/25/2017
RFRR
REFUSAL PROCESSED BY MPU
04/24/2017
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
04/20/2017
CNRT
NON-FINAL ACTION WRITTEN
04/19/2017
MAFR
APPLICATION FILING RECEIPT MAILED
04/18/2017
DOCK
ASSIGNED TO EXAMINER
04/14/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/14/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
04/13/2017
Continuous trademark protection
Get notified about every new filing that threatens VECTURA V or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.